Adicet Bio (ACET) Jefferies 2024 Global Healthcare Conference summary

Key advances in gamma delta T cell therapy

• Gamma delta 1 T cells offer off-the-shelf dosing, no graft-versus-host disease, and do not require gene editing.

• These cells exhibit tissue tropism, targeting organs like kidney, skin, and lungs, which is advantageous for both autoimmune and solid tumor indications.

• Pharmacokinetics (PK) are comparable to autologous therapies, with strong persistence and reduced susceptibility to NK cell attack.

• Manufacturing improvements allow consistent production across multiple sites and CDMOs, with proprietary expansion methods.

• Off-the-shelf approach reduces risk of CAR T cell malignancy and eliminates need for leukapheresis.

Autoimmune program strategy and progress

• ADI-001 targets CD20 for B cell depletion, showing similar PK and efficacy to leading competitors but with better tissue tropism.

• Lupus nephritis chosen as initial indication due to strong proof-of-concept data and clear kidney function endpoints.

• Fast-track FDA designation received, with plans to expand to additional autoimmune indications soon.

• High investigator and site interest, with strong safety profile and comprehensive program expansion expected.

• Lymphodepletion regimen will align with standard protocols, with potential for further reduction.

Oncology pipeline and differentiation

• ADI-270, a CD70-targeted CAR T, uses CD27 as a natural receptor, requiring lower antigen density and providing innate antitumor activity.

• TGF-beta dominant negative receptor added to enhance potency and persistence.

• Program expects higher Cmax, better persistence, and improved tissue penetration, with IND submission planned for Q2 and data expected in the second half of next year.

• Lymphoma trials for ADI-001 show promising results in mantle cell lymphoma (MCL), with durable responses and ongoing enrollment.

• Off-the-shelf CAR T therapy addresses unmet needs by expanding access and improving safety in MCL.